Amendments to the Claims are reflected in the listing of claims which begins on page 4 of this paper.

Remarks/Arguments begin on page 10 of this paper.

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 2, line 31 with the following:

In particular, the present invention relates to the following modified kringle 5 peptides: NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH₂ (SEQ ID NO:17);

NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH2 (SEQ ID NO:18); Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-

Leu-Tyr-Asp-Tyr-Lys-NH2 (SEQ ID NO:19); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Pro-

Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH₂ (SEQ ID NO:20);

NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH2 (SEQ ID NO:21);

NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂ (SEQ ID NO:22);

(MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO:23);

(MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO:24);

NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂ (SEQ ID NO: 25);

(MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO:26);

(MPA)-Tyr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO:27);

NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-

Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH₂ (SEQ ID NO:28);

 $(MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH_2 \ \underline{(SEQ\ ID\ NO:29)};$

(MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO:30);

NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(Nε-MPA)-NH₂ (SEQ ID NO:31); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH₂ (SEQ ID NO:32);

Docket No.: 500862001400

Application No.: 09/657,431

Response to OA of 4/29/05

(MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH₂ (SEQ ID NO:33);

3

NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(NE-MPA)-NH₂ (SEQ ID NO:34);

(MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO:35);

(MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH₂ (SEQ ID NO:36);

NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nε-MPA)-NH₂ (SEQ ID NO:37);

(MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂ (SEQ ID NO:38);

(MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH₂ (SEQ ID NO:39);

NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA-MPA)-NH₂ (SEQ ID NO:40);

NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-($N\epsilon$ -AEEA_n-MPA)-NH₂ (SEQ ID NO:41); and other modified kringle 5 peptides.